Push­ing hard for block­buster re­turns, No­var­tis finds PhI­II da­ta to as­sert Mayzent boosts cog­ni­tive pow­ers in MS pa­tients

A hard-charg­ing group of No­var­tis ex­ecs have been pour­ing over the late-stage da­ta they gath­ered to sup­port their suc­cess­ful cam­paign to win an FDA ap­proval for Mayzent (sipon­i­mod) as a land­mark new ther­a­py for mul­ti­ple scle­ro­sis. And it’s paid off

Crunch­ing the da­ta on their MS drug — tapped as a $1.3 bil­lion block­buster-in-the-mak­ing by Eval­u­ate — re­searchers con­clud­ed that there was clear sta­tis­ti­cal ev­i­dence to show that their drug both pre­served the cog­ni­tive pow­ers of sec­ondary pro­gres­sive MS pa­tients treat­ed ear­li­er in the course of their dis­ease as well boost­ing the abil­i­ty of pa­tients to think. Pa­tients on their drug beat a con­trol group giv­en a place­bo.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER